Urinary exosomal miRNA-451a can be used as a potential noninvasive biomarker for diagnosis, reflecting tubulointerstitial damage and therapeutic response in IgA nephropathy

References

• Pattrapornpisut P, Avila-Casado C, Reich HN. IgA nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;78(3):1–8. doi: 10.1053/j.ajkd.2021.01.024.
   PubMed Web of Science ®Google Scholar
• Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci. 2021;361(2):176–194. doi: 10.1016/j.amjms.2020.10.003.
   PubMed Web of Science ®Google Scholar
• Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727–738. doi: 10.2215/CJN.0000000000000135.
   PubMed Web of Science ®Google Scholar
• Selvaskandan H, Shi S, Twaij S, et al. Monitoring immune responses in IgA nephropathy: biomarkers to guide management. Front Immunol. 2020;11:572754. doi: 10.3389/fimmu.2020.572754.
   PubMed Web of Science ®Google Scholar
• Schena FP, Sallustio F, Serino G. MicroRNAs in glomerular diseases from pathophysiology to potential treatment target. Clin Sci. 2015;128(11):775–788. doi: 10.1042/CS20140733.
   Web of Science ®Google Scholar
• Nalewajska M, Gurazda K, Styczyńska-Kowalska E, et al. The role of MicroRNAs in selected forms of glomerulonephritis. Int J Mol Sci. 2019;20(20):5050. doi: 10.3390/ijms20205050.
   PubMed Web of Science ®Google Scholar
• Wang G, Kwan BC-H, Lai FM-M, et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers. 2010;28(2):79–86. doi: 10.3233/DMA-2010-0687.
   PubMed Web of Science ®Google Scholar
• Altuvia Y, Landgraf P, Lithwick G, et al. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 2005;33(8):2697–2706. doi: 10.1093/nar/gki567.
   PubMed Web of Science ®Google Scholar
• Sayilar EI. Biomarker potential of urine miR-451 at different stages of diabetic nephropathy. J Diabetes Metab. 2016;07(02):100650. doi: 10.4172/2155-6156.1000650.
   Google Scholar
• Kumari M, Mohan A, Ecelbarger CM, et al. MiR-451 loaded exosomes are released by the renal cells in response to injury and associated with reduced kidney function in human. Front Physiol. 2020;11:234. doi: 10.3389/fphys.2020.00234.
   PubMed Web of Science ®Google Scholar
• Li SY, Hao HQ, Li RS, et al. Urinary exosomal MicroRNAs as new noninvasive biomarkers of IgA nephropathy. Tohoku J Exp Med. 2022;256(3):215–223. doi: 10.1620/tjem.256.215.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276. doi: 10.1016/j.kint.2021.05.021.
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91(5):1014–1021. doi: 10.1016/j.kint.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Alvarez ML, Khosroheidari M, Kanchi Ravi R, et al. Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 2012;82(9):1024–1032. doi: 10.1038/ki.2012.256.
   PubMed Web of Science ®Google Scholar
• Delrue C, De Bruyne S, Speeckaert R, et al. Urinary extracellular vesicles in chronic kidney disease: from bench to bedside? Diagnostics. 2023;13(3):443. doi: 10.3390/diagnostics13030443.
   Web of Science ®Google Scholar
• Marques FZ, Campain AE, Tomaszewski M, et al. Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs. Hypertension. 2011;58(6):1093–1098. doi: 10.1161/HYPERTENSIONAHA.111.180729.
   PubMed Web of Science ®Google Scholar
• Groza Y, Jemelkova J, Kafkova LR, et al. IL-6 and its role in IgA nephropathy development. Cytokine Growth Factor Rev. 2022;66:1–14. doi: 10.1016/j.cytogfr.2022.04.001.
   PubMed Web of Science ®Google Scholar
• Sumaiya K, Langford D, Natarajaseenivasan K, et al. Macrophage migration inhibitory factor (MIF): a multifaceted cytokine regulated by genetic and physiological strategies. Pharmacol Ther. 2022;233:108024. doi: 10.1016/j.pharmthera.2021.108024.
   PubMed Web of Science ®Google Scholar
• Kong Y-Z, Chen Q, Lan H-Y. Macrophage migration inhibitory factor (MIF) as a stress molecule in renal inflammation. Int J Mol Sci. 2022;23(9):4908. doi: 10.3390/ijms23094908.
   PubMed Web of Science ®Google Scholar
• Taniguchi Y, Yorioka N, Yamashita K, et al. Macrophage migration inhibitory factor in IgA nephropathy. Kidney Int. 1998;54(6):2245–2246. doi: 10.1038/4499993.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Kanmatsuse K. Urinary levels of macrophage migration inhibitory factor in patients with IgA nephropathy. Nephron. 2002;92(2):309–315. doi: 10.1159/000063297.
   PubMed Web of Science ®Google Scholar
• Xu R-C, Guo J-Y, Cao T, et al. A mixed-method evaluation of the relationship between oxford classification scores and longitudinal changes in proteinuria in patients with immunoglobulin a nephropathy. Front Endocrinol. 2022;13:890900. doi: 10.3389/fendo.2022.890900.
   PubMed Web of Science ®Google Scholar